DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 17.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,178,858 shares of the medical device company’s stock after selling 252,106 shares during the period. Massachusetts Financial Services Co. MA’s holdings in DexCom were worth $91,680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc purchased a new position in DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA boosted its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new stake in DexCom in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Canaccord Genuity Group lifted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Trading Down 3.2 %

NASDAQ:DXCM opened at $59.83 on Friday. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $141.99. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a fifty day simple moving average of $80.14 and a 200-day simple moving average of $76.87. The company has a market capitalization of $23.38 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.